FTSE MIB
34.288,91 +349,16 (+1,03%) Dow Jones
38.201,57 +115,77 (+0,30%) Nasdaq
15.941,53 +329,77 (+2,11%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,43 -0,14 (-0,17%) Bitcoin EUR
59.794,06 +586,51 (+0,99%)
Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
| Chiusura precedente | 33,81 |
| Aperto | 33,48 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 32,85 - 34,14 |
| Intervallo di 52 settimane | 2,82 - 49,65 |
| Volume | |
| Media Volume | 3.322 |
| Capitalizzazione | 22,488M |
| Beta (5 anni mensile) | 2,47 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,31 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireCorbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next ge
- GlobeNewswire
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here. The event will feature several Oncology experts Daniel P.
